POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for cellular homeostasis, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides glucose for energy and to correct hypoglycemia. Sodium chloride provides sodium and chloride ions to maintain electrolyte balance and osmotic pressure.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Sodium and chloride are mainly excreted by the kidneys with minimal metabolism. |
| Excretion | Primarily renal (>90% of potassium and chloride); potassium is reabsorbed and secreted in the distal tubule; dextrose is oxidized to CO2 and water or excreted renally as metabolic products; sodium and chloride are excreted renally; less than 1% fecal or biliary. |
| Half-life | Potassium has a terminal half-life of approximately 12 hours in plasma, but whole-body turnover is slower due to large intracellular stores; distribution half-life is ~1 hour. Dextrose half-life is negligible as it is rapidly metabolized with a half-life of <15 minutes. |
| Protein binding | Potassium: not significantly protein-bound (<2%); sodium: minimal protein binding; chloride: not bound; dextrose: not bound. |
| Volume of Distribution | Potassium: Vd ~0.5-0.6 L/kg (total body water) but predominantly intracellular; clinically, reflects distribution into total body water for potassium. Sodium and chloride distribute primarily extracellular (Vd ~0.2 L/kg). Dextrose distributes into total body water. |
| Bioavailability | IV: 100% bioavailability. Oral/other routes not applicable for this formulation. |
| Onset of Action | IV infusion: Immediate for electrolyte effects (minutes). Oral administration not applicable because this is an IV formulation. |
| Duration of Action | IV: Duration depends on infusion rate and renal function; effects on serum electrolytes last minutes to hours after cessation. Continuous infusion required for sustained correction. |
| Molecular Weight | Potassium chloride: 74.55 Da |
Intravenous infusion; typical adult dose: 1-2 liters over 24 hours, providing potassium at 0.075% (10 mEq/L), dextrose 3.3%, and sodium chloride 0.3%, titrated to electrolyte needs and clinical response.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min). For GFR 30-50 mL/min, reduce infusion rate by 50% and monitor serum potassium closely. For GFR >50 mL/min, no adjustment required unless hyperkalemia develops. |
| Liver impairment | No specific Child-Pugh based dose adjustments; however, avoid in severe hepatic failure due to risk of hyperkalemia and fluid overload. Use with caution in cirrhosis with ascites, monitoring serum potassium and fluid status. |
| Pediatric use | Weight-based dosing: 0.5-1 mEq/kg/day of potassium, infused as part of maintenance fluid. Use 0.075% concentration (10 mEq/L) at 100 mL/kg/day for first 10 kg, then 50 mL/kg/day for next 10 kg, then 20 mL/kg/day for remaining weight. Adjust for deficits and ongoing losses. |
| Geriatric use | Initiate at lower end of dosing range; consider reduced renal function. Monitor for fluid overload and hyperkalemia. Typical infusion rate 1 liter over 24 hours, adjusted based on serum electrolytes, renal function (eGFR), and volume status. |
| 1st trimester | Potassium chloride, dextrose, and sodium chloride are commonly used intravenous fluids. Potassium chloride is essential for cellular function. In therapeutic doses, no teratogenic effects are known. However, use only if clearly needed and monitor serum potassium levels to avoid hyperkalemia. |
| 2nd trimester | Continued use is generally considered safe when clinically indicated. Avoid excessive potassium administration which may cause maternal hyperkalemia and potential fetal arrhythmias. |
| 3rd trimester | Use with caution as fluid and electrolyte balance is critical during labor and delivery. Monitor maternal potassium levels closely; fetal potassium levels correlate with maternal levels. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta readily via active transport. Dextrose crosses by facilitated diffusion, and sodium crosses via active transport. Fetal serum levels reflect maternal levels. |
| Breastfeeding | Potassium, dextrose, and sodium chloride are normal constituents of human milk. Administration of these components in typical intravenous doses does not pose a risk to the nursing infant. However, monitor for maternal electrolyte imbalances which could theoretically affect milk composition. |
| Lactation Rating | L1 |
| Teratogenic Risk | POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER: Potassium chloride at this low concentration is not expected to increase the risk of major birth defects. Dextrose and sodium chloride are normal body constituents; at standard infusion rates, no teratogenic effects are reported. However, electrolyte imbalances (e.g., hyperkalemia, hypernatremia) may occur with excessive administration and could theoretically affect fetal development. First trimester: No known teratogenicity from balanced electrolyte solutions. Second and third trimesters: Risk is primarily from maternal electrolyte disturbances, which can affect fetal homeostasis. Overall, this solution is considered low risk when used appropriately. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, glucose), renal function, and fluid balance. In pregnancy, assess for signs of hyperkalemia (ECG changes, muscle weakness) or hypernatremia (thirst, edema). Fetal monitoring: Standard prenatal care; no specific fetal monitoring required unless maternal electrolyte abnormalities develop. Periodic blood glucose monitoring if administered with dextrose, especially in gestational diabetes or impaired glucose tolerance. |
| Fertility Effects | No adverse effects on fertility are reported with potassium chloride, dextrose, or sodium chloride at therapeutic doses. Electrolyte imbalances from excessive administration could theoretically impair reproductive function, but standard use does not affect fertility. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Rapid infusion may cause hyperkalemia and cardiac arrest. Not for direct IV injection.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHyperglycemia with dextrose contraindication (e.g., severe hyperglycemia without insulin coverage)Pre-existing severe hypernatremiaSevere renal impairment with oliguria or anuria
| Precautions | Risk of hyperkalemia and cardiac arrhythmias, especially in renal impairment, Monitor serum potassium, glucose, and electrolytes frequently, Use with caution in patients with cardiac disease, renal failure, or hyperkalemia, Do not administer unless solution is clear and container is undamaged, Discard any unused portion after single use |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) unless directed by physician. Do not use potassium-containing salt substitutes. |
| Clinical Pearls | Do not administer undiluted; must be infused via central line if concentration >0.05%. Monitor serum potassium and ECG during infusion. Contraindicated in severe hyperkalemia, renal failure, and anuria. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. |
| Patient Advice | Report any chest pain, palpitations, or muscle weakness immediately. · Avoid potassium-containing salt substitutes or supplements without doctor approval. · Inform your healthcare provider if you are on any heart or blood pressure medications. · Do not stop or change the infusion rate on your own. |
Loading safety data…